

# 280 - References

## References

Schizophrenia and related psychoses CHAPTER 1 NFIB rs28379954 T>C CT carriers have much lower blood concentrations than TT carriers in both smokers and non-smokers.<sup>18</sup> Also, the rs2472297 genotype independently predicts clozapine plasma levels.<sup>19</sup> Levels are highest in C/C carriers and lowest in T/T carriers (C/T somewhere in between). Genetic analysis of CYP function can identify the cause of low clozapine blood concentrations and allow selection of appropriate enzyme inhibitors.<sup>20</sup> Other adverse effects Genetic predictors of myocarditis<sup>21</sup> and weight gain<sup>22</sup> have also been found, but associations are probably too weak to allow clinical application.<sup>15</sup>

### References

1. Gressier F, et al. Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis. *Eur Neuropsychopharmacol* 2016; 26:163–185.
2. Athanasiou MC, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. *J Clin Psychiatry* 2011; 72:458–463.
3. Konte B, et al. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. *Transl Psychiatry* 2021; 11:214.
4. Dettling M, et al. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. *Arch Gen Psychiatry* 2001; 58:93–94.
5. Yunis JJ, et al. HLA associations in clozapine-induced agranulocytosis. *Blood* 1995; 86:1177–1183.
6. Saito T, et al. Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese population. *Biol Psychiatry* 2016; 80:636–642.
7. Girardin FR, et al. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. *Pharmacogenomics J* 2019; 19:211–218.
8. Goldstein JL, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. *Nat Commun* 2014; 5:4757.
9. Legge SE, et al. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. *Pharmacogenomics* 2019; 20:279–290.
10. Islam F, et al. Pharmacogenomics of clozapine-induced agranulocytosis: a systematic review and meta-analysis. *Pharmacogenomics J* 2022; 22:230–240.
11. Charles BA, et al. Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia. *PLoS One* 2018;

13:e0194400.

12. Aziri H, et al. Genetic identification of undiagnosed benign ethnic neutropenia in patients receiving clozapine treatment. *Br J Psychiatry* 2024; doi: 10.1192/bjp.2024.236.
13. Olesen OV, et al. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. *J Clin Pharmacol* 2001; 41:823-832.
14. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration: a comparison of a population algorithm and three algorithms based on gene variant models. *J Psychopharmacol* 2023; 37:1030-1039.
15. Thorn CF, et al. PharmGKB summary: clozapine pathway, pharmacokinetics. *Pharmacogenet Genomics* 2018; 28:214-222.
16. Tóth K, et al. Potential role of patients' CYP3A-status in clozapine pharmacokinetics. *Int J Neuropsychopharmacol* 2017; 20:529-537.
17. John AP, et al. Unusually high serum levels of clozapine associated with genetic polymorphism of CYP3A enzymes. *Asian J Psychiatr* 2020; 10:21283.
18. Smith RL, et al. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients: a genome-wide association study adjusting for smoking habits. *Transl Psychiatry* 2020; 10:198.
19. Pardiñas AF, et al. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. *Am J Psychiatry* 2019; 176:477-486.
20. Okon-Rocha E, et al. Genetic analysis of clozapine metabolism in a patient with subtherapeutic clozapine plasma concentrations: the importance of CYP3A5: a case report. *J Clin Psychopharmacol* 2022; 42:604-606.
21. Lacaze P, et al. Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. *Transl Psychiatry* 2020; 10:37.
22. Li N, et al. Progress in genetic polymorphisms related to lipid disturbances induced by atypical antipsychotic drugs. *Front Pharmacol* 2020; 10:1669.

---

Revision #1

Created 2026-01-04 20:13:39 UTC by Omar Ayman

Updated 2026-01-04 20:13:39 UTC by Omar Ayman